Conventional dynamic contrast-enhanced MRI (DCE-MRI) has been used for tumor characterization based on tumor vascularity and permeability using non-targeted small molecular contrast agents. In this study, we investigate the effectiveness of DEC-MRI with a targeted MRI contrast agent for characterization of prostate cancer of different aggressiveness in comparison with a clinical agent. Distinctive Ktrans and Ve values were obtained between the high-risk PC3 and low-risk LNCaP tumors using the targeted agent, but not for the clinical agent, Gd(HP-DO3A). DCE-MRI with this targeted contrast agent could increase accuracy in characterizing prostate cancer aggressiveness.
This abstract and the presentation materials are available to members only; a login is required.